Clinical Trial Update: Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma [Phase 2]

View source ↗

Summary

Phase 2 pediatric trial evaluating pharmacokinetics, safety, and tolerability of a once-daily chewable fevipiprant tablet in children aged 6 to <12 with asthma;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Fevipiprant (fevipiprant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Asthma | Phase 2 | Status: TERMINATED | Results posted: 2020-07-20